Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs
Allogene Therapeutics President and CEO Zachary Roberts was granted 476,190 stock options with an exercise price of $2.11 per share and 134,530 Restricted Stock Units (RSUs). These equity awards are compensation-related and not open-market transactions. The stock options vest over time, with 25% on July 1, 2027, and the remainder in monthly installments, while the RSUs vest in four equal annual installments starting July 20, 2026, both subject to continued service.
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO
The article focuses on the enterprise value to EBITDA forward for Allogene Therapeutics, Inc. (NASDAQ:ALLO). It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific financial metrics are available for the company.
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO
This page provides financial information for Allogene Therapeutics, Inc. (NASDAQ: ALLO), focusing on its Price to Earnings Forward metric. The content highlights the company's stock market data and emphasizes that specific financial values for this metric are presented within the TradingView platform.
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO
This article provides financial information for Allogene Therapeutics, Inc. (ALLO), specifically focusing on its enterprise value to revenue forward. The data is presented within the context of the Blue Ocean Alternative Trade System (BOATS) on the TradingView platform.
Price to sales forward of Allogene Therapeutics, Inc. – BOATS:ALLO
This article provides the "Price to sales forward" metric for Allogene Therapeutics, Inc. (ALLO), listed on the Blue Ocean Alternative Trade System (BOATS). It notes the market is currently closed with no trades. The content is primarily a data point surrounded by navigation and footer information from the TradingView platform.
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO)
This article provides an overview of Allogene Therapeutics, Inc. (NASDAQ: ALLO) financials, stock performance, and analyst forecasts. It includes key figures such as the current stock price, market capitalization, earnings per share, and revenue, alongside analysts' high and low price estimates. The company's next earnings report is scheduled for August 5, 2026, and it currently does not pay dividends.
ALLO Forecast — Price Target — Prediction for 2027
This article provides an overview of Allogene Therapeutics, Inc. (ALLO) stock analysis, including its current price, analyst price targets, and future predictions. It details the company's financial performance, market capitalization, earnings reports, and employee count, alongside a disclaimer that the information provided is not investment advice.
Recent pharma exec shake-ups signal strategic shifts
Recent executive movements at major pharmaceutical companies like Novo Nordisk, Genentech, and Allogene reflect strategic adjustments within the industry. Novo Nordisk saw a significant M&A executive depart, while Genentech underwent leadership layoffs due to pipeline restructuring. Allogene Therapeutics is preparing for a new CEO as it focuses on its CAR-T therapies following promising clinical trial results.
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs
Allogene Therapeutics director Deborah M. Messemer was granted 95,400 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs, which carry no purchase price, give her the contingent right to receive 95,400 shares of Allogene common stock upon vesting. The vesting schedule involves two equal semi-annual installments over a one-year period, conditioned on her continued service through each vesting date.
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Allogene Therapeutics Inc. as of June 23. It includes the company's stock symbol ALLO and its current price performance, noting a -1.43% change. The content primarily states the filing without providing further details or analysis within the main body.
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award
Allogene Therapeutics director Vicki L. Sato was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two equal semi-annual installments over one year, contingent on her continued service. The filing, a Form 4, indicates this is an equity award and does not involve any open-market purchases or sales by the director.
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant
Allogene Therapeutics director Stephen Mayo was granted 144,400 stock options with an exercise price of $2.00 per share. These options vest in 12 equal monthly installments and expire on June 18, 2036. Following this grant, Mayo holds options for 144,400 shares of Allogene common stock.
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery
Allogene Therapeutics, Inc. (ALLO) director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two semi-annual installments over one year, contingent on her continued service. Barrett has opted to defer the delivery of the underlying shares until she leaves continuous service or a change in control of the company occurs.
Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan
Allogene Therapeutics (NASDAQ: ALLO) announced that its stockholders approved an increase in authorized common shares from 400 million to 800 million at the 2026 Annual Meeting. This change, effective June 18, 2026, provides the company with greater flexibility for future equity issuances. Additionally, Allogene filed a prospectus supplement for an at-the-market (ATM) offering, allowing the sale of up to $135.0 million in common stock through TD Securities (U.S.A.) LLC.
ALLO: All proposals, including director elections and share increase, were approved without contest
Allogene Therapeutics, Inc. (ALLO) held its 2026 AGM where all five key proposals were approved unanimously. These proposals included director elections, executive compensation, annual advisory votes, an increase in authorized shares, and auditor ratification. No questions were raised during the meeting.
Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Allogene Therapeutics Inc (ALLO), including business segments, regional revenue, and profit contribution. However, the core information indicates that the relevant financial data has not yet been disclosed by the company. Therefore, no specific details regarding the company's revenue segmentation are available in the article.
10 Small Cap Stocks with Potential to Rise 1000 Percent
This article highlights small-cap stocks with significant growth potential, focusing on Allogene Therapeutics, Inc. (NASDAQ:ALLO) as a key example. Allogene is a clinical-stage biotechnology company developing CAR T cell therapies for cancer and autoimmune diseases, with important trial results and an extended cash runway expected in the near future. The company's progress in its Phase 2 ALPHA3 trial for large B-cell lymphoma and initial data from its Phase 1 RESOLUTION trial for autoimmune diseases position it as a promising investment.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut
DelveInsight projects the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market to be a high-growth healthcare investment space through 2036, driven by rising NHL prevalence and advancements in CAR T-cell therapies. The report highlights key companies like Gilead Sciences, Novartis, and BMS, and notes that the US market for CAR T-cell therapy in NHL was approximately USD 1,900 million in 2025 and is expected to grow significantly. The total incident cases of selected CAR-T indications in NHL across the 7MM were around 159,000 in 2025, with DLBCL being the most common subtype.
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
Allogene Therapeutics (ALLO) is highlighted as a top penny stock due to its robust CAR T-cell therapy pipeline, including positive interim results for cema-cel in the ALPHA3 trial and development of ALLO-329 for autoimmune disease. The company reported a net loss of $42.6 million in Q1 but has a cash runway into Q1 2029, supporting its clinical-stage biotechnology efforts in "off-the-shelf" CAR T cell therapies.
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’
Allogene Therapeutics (ALLO) shares surged over 50% to a two-year high after interim Phase 2 trial data for Cema-Cel in treating lymphoma showed significant efficacy. The data revealed 58.3% of treated patients had no detectable disease and a 97.7% drop in cancer DNA levels, leading TD Cowen to maintain a 'Buy' rating and call the results a "home run." The trial, which was generally well tolerated, aims to enroll 220 patients by 2027, with the company anticipating regulatory approval if positive results continue.
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test
David Chang, co-founder of Allogene Therapeutics Inc., is stepping down as CEO at the end of June. This leadership change occurs as the company is conducting a critical clinical trial for a potential regulatory approval of its lymphoma treatment. The San Francisco Business Times is also seeking nominations for its C-Suite Leaders Awards.
Allogene Therapeutics Names Zachary Roberts as New CEO
Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the board, bringing extensive oncology and cell therapy experience to the role. His compensation package includes a base salary of $680,000, a significant stock option and RSU package, and eligibility for severance benefits, aligning his interests with shareholders.
Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.
Allogene Therapeutics, Inc. has common stock subject to a lock-up agreement that ends on May 30, 2026. The lock-up period began on April 14, 2026, and prevents the company's directors and executive officers from disposing of or hedging common stock or related securities for 45 days without underwriter consent. This measure is standard for certain offerings to ensure market stability post-issuance.
CMO Roberts to succeed Chang as Allogene CEO
Zachary Roberts, currently EVP of R&D and CMO of Allogene Therapeutics Inc. (NASDAQ:ALLO), will take over as president and CEO on July 1. He will also join the board. David Chang, a co-founder who has led the company for eight years, will remain on the board.
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026.
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a lock-up agreement that ends on May 30, 2026. These units were locked up for 46 days starting on April 14, 2026. The agreement restricts the disposal or hedging of common stock or convertible securities by the company, its directors, and executive officers for a specified period after the prospectus supplement date.
Allogene Therapeutics Names Zachary Roberts as New CEO
Allogene Therapeutics has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently the executive vice president of R&D and chief medical officer, will also join the board. His compensation package includes a significant stock option and RSU grant, aligning his incentives with shareholder interests while Allogene focuses on advancing its allogeneic cell therapies for cancer.
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10
Piper Sandler has reiterated its Buy rating for Allogene Therapeutics (ALLO.US) and maintained its price target of $10. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Press Release: Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics has announced a planned CEO succession, with Dr. David Chang transitioning from President and CEO to Executive Chairman. Eric Schmidt will assume the role of President and CEO, bringing extensive experience in cell therapy and oncology. This leadership transition aims to strengthen Allogene's position in the cell therapy field.
Allogene Therapeutics names Zachary Roberts as new CEO By Investing.com
Allogene Therapeutics (NASDAQ:ALLO) has appointed Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding co-founder David Chang. Roberts, currently EVP of R&D and Chief Medical Officer, will also join the Board of Directors. The company, focused on allogeneic CAR T products, reported positive interim results for its ALPHA3 trial and, despite being unprofitable, maintains a strong balance sheet with significant cash reserves.
Allogene Therapeutics (ALLO) elevates Zachary Roberts to CEO with major equity awards
Allogene Therapeutics has announced the appointment of Zachary Roberts, M.D., Ph.D. as its new President and Chief Executive Officer, effective July 1, 2026. He will succeed David Chang, M.D., Ph.D., who will remain on the Board as a non-employee director. Dr. Roberts' compensation package includes a $680,000 base salary, a 60% target cash incentive, and significant equity awards consisting of 476,190 stock options and 134,530 restricted stock units, all subject to service-based vesting.
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced a planned CEO succession, with Dr. David Chang transitioning from his role as President and Chief Executive Officer effective June 30, 2026, after eight years. Dr. Zachary Roberts, currently EVP, Research & Development and Chief Medical Officer, will succeed him as President and CEO, effective July 1, 2026, and will also join the Board of Directors. Dr. Chang will continue to serve on the Company’s Board.
Allogene Therapeutics names Zachary Roberts as new CEO
Allogene Therapeutics has announced that Zachary Roberts will become its new President and CEO beginning July 1, succeeding co-founder David Chang. Roberts, currently EVP of Research & Development and Chief Medical Officer, will also join the Board of Directors. The company develops allogeneic CAR T products and maintains a strong balance sheet despite being unprofitable.
ALLO Stock Steadies As Cash Runway Extends To 2029 On Trial Progress
Allogene Therapeutics Inc. (ALLO) stock rose by 7.08% due to positive sentiment surrounding its clinical trial progress. The company's Q1 EPS came in at -$0.18, slightly better than expected, and a $200M equity raise extended its cash runway into Q1 2029. Interim Phase 2 ALPHA3 cema-cel data showed encouraging efficacy and outpatient feasibility, along with an advancing autoimmune program.
Cancer cell therapy firm Allogene lines up three investor talks
Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotechnology company focused on CAR T therapies for cancer and autoimmune diseases, announced its participation in three upcoming investor conferences. The conferences include TD Cowen’s Oncology Innovation Summit, Jefferies Global Healthcare Conference, and H.C. Wainwright’s Cell Therapy Virtual Conference during late May and early June 2026. The company noted that webcasts and replays of these presentations would be available on its website, and its stock saw a positive market reaction, gaining 6.00% on the news.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. announced its participation in three upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The clinical-stage biotechnology company specializes in developing allogeneic CAR T products for cancer and autoimmune diseases. Webcasts of the presentations will be available on the company's website.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. announced its participation in three upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune disease. Webcasts of the presentations will be available on their website.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in three upcoming investor conferences in late May and early June 2026. The clinical-stage biotechnology company will present at the TD Cowen 7th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference, and H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Webcasts of these presentations will be available on the company's website.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc. announced its participation in three upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit on May 26, the Jefferies Global Healthcare Conference on June 3, and the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 9. The biotechnology company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases. Webcasts of these presentations will be available on the company's website.
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO)
This article provides a list of recent news and financial updates for Allogene Therapeutics Inc (NASDAQ:ALLO). Key highlights include reports on Q4 2025 and Q1 2026 financial results, which showed narrower-than-expected losses, and announcements regarding upcoming investor conference participations. The company has also reported progress in its pipeline and key clinical catalysts for 2026.
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment
Allogene Therapeutics is advancing its ALPHA3 clinical trial to investigate allogeneic CAR T therapies for large B-cell lymphoma (LBCL). Dr. Zachary Roberts, EVP of R&D and CMO, highlighted the potential of off-the-shelf cell therapy to transform LBCL treatment. The company also recently provided a Q1 report emphasizing its progress in allogeneic CAR T development, demonstrating its commitment to cell therapy advancements.
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss
Allogene Therapeutics reported mixed Q1 2026 results, exceeding EPS expectations at -$0.18 but missing revenue forecasts entirely with $0 reported. The company announced positive interim results for its ALPHA3 trial, showing a 58.3% MRD clearance rate, and extended its cash runway into Q1 2029 through a recent public offering. Despite a post-earnings stock drop, premarket trading showed a slight recovery, reflecting investor confidence in its clinical progress and financial stability.
Allogene Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.18) — 10-Q Summary
Allogene Therapeutics, Inc. reported a Q1 2026 net loss of $42.6M and diluted EPS of $(0.18), marking an improvement from the previous year, with revenue remaining at $0. The company is advancing its ALPHA3 Phase 2 trial and other key programs while implementing operational efficiencies and workforce reductions. They also received RMAT and Fast Track designations for some of their clinical candidates.
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO
This article provides financial information for Allogene Therapeutics, Inc. (BOATS:ALLO), specifically focusing on the number of shareholders. It appears to be a financial data page from TradingView, offering an overview of the company's financials without detailed analysis in the provided content. The page also lists various services and resources available on the TradingView platform.
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO)
A Schedule 13G/A filing indicates that Citadel-related entities and Kenneth Griffin have reported shared beneficial ownership of Allogene Therapeutics (ALLO) common stock. Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each report holding 2.4% of outstanding shares, while Kenneth Griffin personally holds 2.8%. These disclosures specify the percentages based on Allogene's 243,777,920 shares outstanding as of March 10, 2026, as per the issuer's Form 10-K.
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake
Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G/A for Allogene Therapeutics (NASDAQ: ALLO), reporting a 0% beneficial ownership stake. This administrative amendment indicates that the reporting persons hold 0 shares, categorizing their position as "Ownership of 5 percent or less of a class" and suggesting a purely procedural update with no material change in holdings.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. discussed its Q1 2026 earnings, highlighting progress in its SemiCell and ALLO-329 clinical programs. The ALPHA-3 trial for SemiCell in large B cell lymphoma showed promising interim futility analysis results, with significant MRD clearance and a favorable safety profile, making outpatient administration feasible. The ALLO-329 program for autoimmune diseases is efficiently progressing through dose escalation, demonstrating early signs of clinical activity and tolerability even at lower doses. The company also confirmed a strong financial position, extending its cash runway into 2029.
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)
This article highlights bullish analyst ratings for three healthcare companies: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN), and Alkermes (ALKS). Analysts from TD Cowen and RBC Capital maintained Buy ratings for these companies, citing strong prospects and setting price targets indicating significant upside potential from current share prices. The consensus for all three stocks is a "Strong Buy."
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics announced its Q1 2026 financial results, reporting a net loss of $42.6 million and ending the quarter with $266.9 million in cash. The company provided an update on its clinical programs, including positive interim futility analysis from the ALPHA3 trial for cema-cel in LBCL and ongoing dose escalation in the ALLO-329 RESOLUTION trial for autoimmune disease. Allogene anticipates an interim Event-Free Survival analysis for ALPHA3 in mid-2027 and expects to extend its cash runway into Q1 2029 following a recent public offering.
Allogene Therapeutics Q1 Net Loss Narrows
NULL
Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing
Allogene Therapeutics has entered into a termination agreement with Overland Therapeutics, effective May 12, 2026. This information was disclosed via an SEC filing.
